Although there are also no cases recorded of measles in any individual receiving an IL-17 inhibitor, an IL-12/23 inhibitor, or an IL-23 inhibitor, but a report exists of measles in a patient with rheumatoid arthritis on etanercept, a tumor necrosis factor (TNF) alpha inhibitor, that resulted in severe leukopenia and hospitalization (Takahashi et al., 2010). This evidence concerns the gene IL17A and measles.